Natriumtiosulfat Hope (Sodium Thiosulfate)

What Is Natriumtiosulfat Hope and What Is It Used For?

Natriumtiosulfat Hope contains sodium thiosulfate (Na₂S₂O₃), an inorganic compound that has been used in clinical medicine for over a century. The compound is classified as an antidote and cytoprotective agent, and it is supplied as a sterile, clear, colorless to slightly yellow aqueous solution for intravenous injection at a concentration of 250 mg/ml.

Sodium thiosulfate has a unique pharmacological profile that makes it valuable across several distinct clinical applications. Its primary mechanism of action involves serving as an exogenous sulfur donor for the mitochondrial enzyme rhodanese (thiosulfate sulfurtransferase). This enzyme catalyzes the transfer of sulfur from thiosulfate to cyanide, producing thiocyanate — a compound that is approximately 200 times less toxic than cyanide and is readily excreted by the kidneys.

The drug has gained prominence in three major clinical contexts. First, it remains a cornerstone of emergency treatment for cyanide poisoning, whether from industrial exposure, smoke inhalation in structural fires, or iatrogenic causes such as sodium nitroprusside toxicity. In this setting, it is often administered as part of a cyanide antidote protocol alongside sodium nitrite or hydroxocobalamin.

Second, sodium thiosulfate has been approved by the U.S. Food and Drug Administration (FDA) under the brand name Pedmark for the prevention of cisplatin-induced ototoxicity in pediatric patients aged 1 month and older with localized, non-metastatic solid tumors. Cisplatin is one of the most effective and widely used chemotherapy agents, but it causes irreversible sensorineural hearing loss in up to 60% of pediatric patients. Sodium thiosulfate binds to and inactivates cisplatin that has entered the cochlear hair cells, thereby protecting them from damage.

Third, sodium thiosulfate is increasingly used off-label for the treatment of calciphylaxis (calcific uremic arteriolopathy), a rare but devastating condition that predominantly affects patients with end-stage renal disease. In this condition, calcium deposits in small blood vessels lead to tissue ischemia, necrosis, and extremely painful skin lesions. Sodium thiosulfate acts as a calcium chelator, helping to dissolve vascular calcium deposits and improve tissue perfusion. Several case series and observational studies have demonstrated clinical benefit, though large randomized controlled trials are still limited.

Mechanism of Action

The pharmacological activity of sodium thiosulfate is multifaceted. In cyanide detoxification, it provides sulfane sulfur to rhodanese, accelerating the conversion of cyanide (CN⁻) to thiocyanate (SCN⁻). The body's endogenous rhodanese pathway has limited capacity due to insufficient sulfur substrate availability; exogenous sodium thiosulfate dramatically increases the rate of cyanide detoxification.

In cisplatin otoprotection, sodium thiosulfate acts through direct chemical inactivation. It forms a stable, non-toxic complex with cisplatin (sodium thiosulfate–cisplatin adduct), effectively neutralizing the platinum compound before it can damage cochlear outer hair cells. The timing of administration relative to cisplatin infusion is critical: it must be given after a sufficient interval to avoid reducing the antitumor efficacy of cisplatin.

In calciphylaxis, the mechanism involves calcium chelation. Sodium thiosulfate forms soluble calcium thiosulfate complexes, which can then be cleared from the body. This process helps dissolve the pathological vascular calcifications that characterize the disease. Additionally, sodium thiosulfate possesses antioxidant and vasodilatory properties that may contribute to its therapeutic effect in this condition.

What Should You Know Before Taking Natriumtiosulfat Hope?

Before sodium thiosulfate is administered, healthcare providers must conduct a thorough assessment of the patient's medical history, current medications, and clinical status. While the drug has a relatively favorable safety profile, several important contraindications, warnings, and precautions must be considered to ensure safe and effective use.

Contraindications

The primary contraindication to sodium thiosulfate is known hypersensitivity to sodium thiosulfate or any of the excipients in the formulation. Allergic reactions, while rare, can include urticaria, angioedema, and in severe cases, anaphylaxis. In the emergency setting of cyanide poisoning, the life-threatening nature of the condition generally outweighs the risk of allergic reaction, but clinicians should still be prepared to manage hypersensitivity.

There are no absolute contraindications to the use of sodium thiosulfate in confirmed cyanide poisoning, as the untreated condition is rapidly fatal. However, for non-emergency indications such as calciphylaxis or cisplatin otoprotection, the risk-benefit assessment is more nuanced and should include consideration of the patient's overall clinical status.

Warnings and Precautions

Hypotension: Rapid intravenous administration of sodium thiosulfate can cause significant hypotension. The drug should be infused slowly over 10 to 20 minutes, and blood pressure should be monitored throughout the infusion. Patients who are already hemodynamically unstable (as is common in severe cyanide poisoning) require particularly careful monitoring.

Renal impairment: Thiocyanate, the primary metabolite of sodium thiosulfate, is eliminated renally. In patients with significant renal impairment or end-stage renal disease, thiocyanate may accumulate, leading to toxicity. Symptoms of thiocyanate toxicity include tinnitus, muscle spasms, and in severe cases, seizures. In patients receiving sodium thiosulfate for calciphylaxis who are on hemodialysis, the drug should be administered during or immediately after dialysis sessions to facilitate clearance.

Hypernatremia: Sodium thiosulfate contains a significant sodium load. At the typical adult dose of 12.5 g, approximately 113 mEq of sodium is administered. This can be clinically relevant in patients with heart failure, severe hypertension, or conditions requiring sodium restriction. Serum sodium levels should be monitored in patients receiving repeated doses.

Metabolic acidosis: The metabolism of sodium thiosulfate produces sulfate and hydrogen ions, which can contribute to metabolic acidosis. This is particularly relevant in patients who already have acidosis from cyanide poisoning or renal failure. Arterial blood gas monitoring is recommended.

Pregnancy and Breastfeeding

There are limited human data on the use of sodium thiosulfate during pregnancy. Animal reproductive studies are insufficient to establish safety. In the context of life-threatening cyanide poisoning, the benefit of treatment to the mother clearly outweighs potential fetal risk, and treatment should not be withheld.

For non-emergency indications (calciphylaxis, cisplatin otoprotection), the decision to use sodium thiosulfate during pregnancy should be made on an individual basis following careful risk-benefit assessment. Sodium thiosulfate is classified as a category C drug by the FDA for pregnancy.

It is not known whether sodium thiosulfate or its metabolites are excreted in human breast milk. Given the intravenous route of administration and the clinical settings in which it is used, breastfeeding considerations are generally secondary to the primary treatment goals. Healthcare providers should advise patients on an individual basis.

How Does Natriumtiosulfat Hope Interact with Other Drugs?

Drug interactions with sodium thiosulfate are primarily related to its chemical reactivity. As a potent reducing agent and sulfur donor, sodium thiosulfate can directly react with and inactivate several drugs. Understanding these interactions is essential for safe and effective clinical use.

The most important clinical interaction is with cisplatin. Sodium thiosulfate was specifically developed as an otoprotective agent because of its ability to chelate and inactivate cisplatin. However, this same property means that if sodium thiosulfate is administered too close in time to cisplatin, it can reduce the antitumor efficacy of the chemotherapy. Clinical protocols typically require a minimum interval of 6 hours between cisplatin infusion completion and sodium thiosulfate administration. The FDA-approved protocol for Pedmark specifies administration 6 hours after the end of cisplatin infusion.

Major Interactions

The interaction between sodium thiosulfate and cisplatin is the most clinically critical. Sodium thiosulfate forms a stable, pharmacologically inactive platinum–thiosulfate complex. While this is the desired mechanism for otoprotection, systemic exposure to sodium thiosulfate during active cisplatin treatment can significantly reduce the cytotoxic activity of the chemotherapy. Clinical studies have shown that administering sodium thiosulfate 6 hours after cisplatin completion does not compromise antitumor efficacy, as cisplatin rapidly binds to DNA and proteins within tumor cells during the first few hours after infusion.

When used alongside hydroxocobalamin (another cyanide antidote), the two agents can form chemical complexes that may reduce the effectiveness of both. Current clinical guidelines recommend administering them via separate intravenous lines and avoiding simultaneous infusion. In practice, hydroxocobalamin is increasingly preferred as a first-line agent in many European countries due to its favorable safety profile, with sodium thiosulfate reserved as an adjunct or alternative.

Minor Interactions

Sodium thiosulfate may theoretically interact with oxidizing agents and halogen-containing compounds due to its reducing properties. However, these interactions are rarely clinically significant. There are no known significant interactions with common medications such as antihypertensives, antibiotics, or anticoagulants when sodium thiosulfate is used at standard therapeutic doses.

What Is the Correct Dosage of Natriumtiosulfat Hope?

The dosage of Natriumtiosulfat Hope varies significantly depending on the clinical indication, patient age, weight, and renal function. All doses must be calculated and administered by qualified healthcare professionals. The following dosing guidelines are based on current international consensus and regulatory approvals.

Adults

Children

Elderly

There are no specific dose adjustments for elderly patients based on age alone. However, elderly patients are more likely to have impaired renal function, which can affect thiocyanate clearance. Renal function should be assessed before dosing, and serum thiocyanate levels may need to be monitored in patients with reduced creatinine clearance. Sodium loading is also a greater concern in elderly patients with cardiovascular comorbidities.

Missed Dose

Sodium thiosulfate is not a medication taken on a regular schedule by patients at home. In the emergency treatment of cyanide poisoning, there is no concept of a "missed dose" — the drug is given as a single emergency intervention. For calciphylaxis patients receiving thrice-weekly infusions, a missed session should be rescheduled as soon as possible, but double-dosing is not recommended. For cisplatin otoprotection, the dose is tightly linked to chemotherapy cycles and must be coordinated with the oncology team.

Overdose

Overdose of sodium thiosulfate is uncommon in clinical practice. In cases of accidental overdose, the primary concerns are:

• Severe hypotension — manage with IV fluids, vasopressors if necessary, and slowing or stopping the infusion
• Hypernatremia — monitor serum sodium and correct with hypotonic fluids if needed
• Metabolic acidosis — monitor arterial blood gases; sodium bicarbonate may be considered for severe acidosis
• Thiocyanate toxicity (with renal impairment) — symptoms include disorientation, psychosis, muscle twitching, and seizures. Hemodialysis effectively removes thiocyanate

No specific antidote for sodium thiosulfate overdose exists. Treatment is supportive and symptomatic. In patients with normal renal function, thiocyanate is rapidly cleared and the prognosis following overdose is generally good.

What Are the Side Effects of Natriumtiosulfat Hope?

The safety profile of sodium thiosulfate has been established through decades of clinical use in cyanide poisoning treatment and, more recently, through clinical trials for cisplatin otoprotection and calciphylaxis. Overall, the drug is considered to have a favorable risk-benefit profile, particularly in its primary indication of cyanide poisoning where the alternative is death.

It is important to note that in the emergency treatment of cyanide poisoning, distinguishing adverse drug reactions from symptoms of the underlying poisoning is extremely challenging. Many of the reported "side effects" (hypotension, nausea, disorientation) are also cardinal features of cyanide toxicity itself.

Patients receiving sodium thiosulfate for calciphylaxis on a chronic basis (thrice-weekly infusions) may experience cumulative effects, particularly nausea and metabolic acidosis. These can sometimes be managed by adjusting the infusion rate, administering antiemetics, and monitoring acid-base status. The sodium load from repeated dosing can be clinically significant in patients with volume overload or heart failure.

In the cisplatin otoprotection setting, clinical trials (including the pivotal COG ACCL0431 study) reported that sodium thiosulfate was associated with a slightly higher rate of nausea and vomiting compared to placebo, but the overall tolerability was acceptable. There was no evidence that sodium thiosulfate worsened the toxicity profile of cisplatin chemotherapy beyond its expected effects.

How Should You Store Natriumtiosulfat Hope?

Proper storage of Natriumtiosulfat Hope is essential to maintain the stability and efficacy of the product. As a hospital-use medication, storage is primarily the responsibility of pharmacy and nursing staff, but understanding these requirements is important for quality assurance.

The solution should be stored at controlled room temperature, typically between 15°C and 25°C (59°F to 77°F). Brief excursions to temperatures between 8°C and 30°C may be permitted, but prolonged exposure to extreme temperatures should be avoided. The product should be protected from direct light and stored in the original carton until ready for use.

Natriumtiosulfat Hope does not contain preservatives. Once the ampoule or vial is opened, the solution should be used immediately. Any unused portion should be discarded and not saved for later use. This is a standard precaution for preservative-free injectable medications to prevent microbial contamination.

Before administration, healthcare professionals should visually inspect the solution. It should be clear and colorless to slightly yellow. Do not use the product if it is turbid, contains visible particles, or shows signs of discoloration beyond a faint yellow tint. Do not freeze the solution, as this may cause precipitation of the active ingredient.

Keep all medications out of the reach and sight of children. Do not use the product after the expiry date printed on the label and carton. The expiry date refers to the last day of that month. Medicines should not be disposed of via wastewater or household waste; ask your pharmacist about proper disposal methods.

What Does Natriumtiosulfat Hope Contain?

Natriumtiosulfat Hope is a straightforward pharmaceutical formulation with a limited number of ingredients, which is typical for intravenous solutions used in emergency medicine.

Active ingredient: Sodium thiosulfate pentahydrate, equivalent to 250 mg/ml of sodium thiosulfate (Na₂S₂O₃). The pentahydrate form (Na₂S₂O₃·5H₂O) is the most commonly used pharmaceutical grade of the compound. The molecular weight of the anhydrous form is 158.11 g/mol, while the pentahydrate is 248.18 g/mol.

Excipients:

• Water for injections — the solvent vehicle meeting pharmacopeial standards for sterile injectable preparations
• Sodium hydroxide and/or hydrochloric acid — used for pH adjustment to maintain the solution within the optimal pH range (typically 6.0–9.5)

The product does not contain preservatives, antimicrobial agents, antioxidants, or any other additives. This simple formulation minimizes the risk of excipient-related adverse effects and makes the product suitable for use in patients with known sensitivities to common pharmaceutical additives.

Each milliliter of solution contains approximately 1.13 mEq of sodium. At the standard adult cyanide antidote dose of 50 ml (12.5 g), the total sodium load is approximately 56.5 mEq. This should be taken into account in patients requiring sodium restriction.